Coleman Supportive Oncology Initiative
Palliative Training Module
Topic: Pain Management: Beyond the Basics

Presenters: Shelly Lo, MD and Joanna Martin, MD; updated by Christine B. Weldon, MBA and Betty Roggenkamp, BA.

Version: 08282018
Learning Objectives

By the end of this module you should be able to:

1. Explain treatment options for pain management, including opioids and adjuvant pain medications
2. Describe opioid pharmacology
3. Discuss optimal dosing of opioids
4. Convert from one opioid to another

We suggest you do the Palliative Training Course, “Pain Assessment: The Basics”, before this course.
## Treatment Options:

<table>
<thead>
<tr>
<th>Pain Medications</th>
<th>Psychosocial/Behavioral coping strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WHO Ladder</strong></td>
<td><strong>Spiritual Intervention</strong></td>
</tr>
<tr>
<td>Around-the-clock</td>
<td><strong>Physical Activity</strong></td>
</tr>
<tr>
<td>administration of:</td>
<td><strong>Massage, Music, Art Therapy</strong></td>
</tr>
<tr>
<td>• Nonopioids for mild pain</td>
<td><strong>TLC Treatment</strong></td>
</tr>
<tr>
<td>• Mild opioids (codeine) for moderate pain</td>
<td>• Keep clean and dry</td>
</tr>
<tr>
<td>• Strong opioids</td>
<td>• Position comfortably</td>
</tr>
<tr>
<td><strong>Adjuvant medications</strong></td>
<td>• Provide reassuring words</td>
</tr>
<tr>
<td>• Drugs not usually thought of as analgesics</td>
<td>• Give human touch</td>
</tr>
<tr>
<td>• May help relieve pain not fully responsive to opioids</td>
<td></td>
</tr>
</tbody>
</table>

Opioid Pharmacology

- In 2014, 28,647 deaths in the US involved opioid analgesics. Most overdoses on opioids not prescribed to the person are from opioids given by friends or family.
- Majority of opioids are conjugated in the liver
- 90-95% are excreted by kidneys
- Reach their peak analgesic effect approximately:
  - 60 to 90 minutes after oral administration (including enteral feeding tube) or rectal administration
  - 30 minutes after subcutaneous, intramuscular
  - 6 minutes after intravenous injection
  - Steady state plasma concentrations usually attained within 1 day
- Half life of 3-4 hours, reaches a steady state after 4-5 half-lives

U.S. Food and Drug Administration, Full prescribing information for morphine sulfate injection USP. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202515s000lbl.pdf
Optimal Dosing of Opioids: Around-the-Clock (ATC) Dosing

PRN Dosing

ATC Dosing

Reprinted from The Permanente Journal, Fall;9(4), Whitten, Donovan, Cristobal, Treating chronic pain: new knowledge, more choices, 9-18: Figure 7 and Figure 8, (2005), with permission from ©The Permanente Press. www.thepermanentejournal.org
Short Acting Oral Opioids

- **Examples of short acting oral opioids are:**
  - Codeine
  - Hydrocodone
  - Morphine
  - Hydromorphone
  - Oxycodone

- **Analgesic requires a minimum of 60 minutes to reach peak effect, with an expected total duration of analgesia of 2-4 hours**
  - Dose every 4 hours
  - Adjust dose daily
    - Mild/moderate pain: increase by 25-50%
    - Severe/uncontrolled pain: increase by 50-100%
  - Adjust more quickly for severe, uncontrolled pain as necessary; can be dosed every 2 hours
  - After 2-3 cycles, for subsequent management and treatment

See NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adult Cancer Pain, PAIN-6

For additional resources, see also: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Adult Cancer Pain
Fast Facts and Concepts #18, Medical College of Wisconsin, Short-Acting Oral Opioid Dosing Intervals, 2nd ed
Extended-Release Opioids--Oral

- Improve compliance and adherence
- Calculate total opioid dose used in 24 hours
- Convert to a long-acting opioid dose
  - Morphine ER, oxycodone ER, fentanyl patch
- Oral dosing every 8, 12, or 24 hours (product-specific)
  - Do not crush or chew tablets
  - May flush time-release granules down feeding tubes
- Adjust dose every 2-4 days (once steady state is reached)

For additional resources, see also NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Adult Cancer Pain
Extended Release Opioids--Transdermal Fentanyl Patch

- Convenient, non-oral administration
- Replace patch every 72 hours for most patients
- Therapeutic blood levels reached 13-24 hours after patch application
- Drug will continue to be released into the blood for at least 24 hours after patch removal
- Place patches on non-irradiated, hairless skin
- WARNING - Direct heat applied over the patch can increase drug absorption with increased toxic effects
- There are no data that cachectic patients have reduced efficacy due to loss of subcutaneous fat

For additional resources, see also NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Adult Cancer Pain
Breakthrough Pain Dosing of Opioids

- **Use Short-acting opioids for breakthrough pain:**
  - 10-20% of total 24 hour dose\(^1\)
  - Offer after steady state plasma concentrations reached
    - Oral (PO, PR) \(\approx\) every 1 hour
    - Subcutaneous (SC, IM) \(\approx\) every 30 minutes
    - Intravenous (IV) \(\approx\) every 10–15 minutes

- **Do NOT** use extended-release opioids for breakthrough

---

\(^1\)Goroll A., Mulley, A., (2014) Primary Care Medicine: office evaluation and management of the adult patient. For additional resources, see also NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\(^\text{®}\)) Adult Cancer Pain.
Opioid Conversion

1. Calculate total daily dose of opioid, including as-needed doses

2. Convert to another opioid, using equi-analgesic table:
   See NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adult Cancer Pain, Table 1 PAIN-E (7 and 9 of 12)

3. If pain control is good, reduce dose by 25-50% (to allow for incomplete cross-tolerance between opioids); no dose reduction if pain control is poor

4. Re-assess in 1-3 days
Opioid Conversion Case

How to convert hydromorphone 2 mg IV q3 hours given around the clock to extended-release morphine dosed q12 to short acting oral opioids for breakthrough (assuming adequate pain control)?

1. Calculate the 24 hr current dose of IV hydromorphone:
   \[2 \text{ mg} \times 8 \text{ doses} = 16 \text{ mg of hydromorphone in 24 hours}\]

2. To convert from IV hydromorphone to oral morphine:
   Equi-analgesic ratio of IV hydromorphone to oral morphine:
   \[16 \text{ mg hydromorphone} = 320 \text{ mg oral morphine (20:1 ratio)}\]

3. Reduce dose by 25-50\% if adequate pain control:
   \[75\% \text{ of } 320 \text{ mg} = 240 \text{ mg/day of oral morphine} \]
   Can be divided in 2 daily doses of 120 mg (MS ER 60 mg, 2 tabs BID),
   or more conservatively at MS ER 100 mg, 1 tab BID

4. Calculate PRN dose (approx. 10\% of total daily opioid dose):
   \[10\% \text{ of } 240 \text{ mg morphine} = 24 \text{ mg}\]
   Can be given as a 1 ml of a 20 mg/ml solution (20 mg),
   1 morphine sulfate immediate release 15 mg tab (15 mg),
   1.5 tabs of morphine sulfate immediate release 15 mg (22.5 mg) or
   1 morphine sulfate immediate release 30 mg tab (30 mg)
### OPIOID PRINCIPLES, PRESCRIBING, TITRATION, MAINTENANCE, AND SAFETY (7 of 13)

#### Table 1. Oral and Parenteral Opioid Equivalences and Relative Potency of Drugs as Compared with Morphine Based on Single-Dose Studies

<table>
<thead>
<tr>
<th>Opioid Agonists</th>
<th>Parenteral Dose</th>
<th>Oral Dose</th>
<th>Factor (IV to PO)</th>
<th>Duration of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine⁴,⁵</td>
<td>10 mg</td>
<td>30 mg</td>
<td>3</td>
<td>3–4 h</td>
</tr>
<tr>
<td>Hydromorphone⁴</td>
<td>1.5 mg</td>
<td>7.5 mg</td>
<td>5</td>
<td>2–3 h</td>
</tr>
<tr>
<td>Fentanyl⁶</td>
<td>0.1 mg</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Methadone⁷,⁸</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>–</td>
<td>15–20 mg</td>
<td>–</td>
<td>3–5 h</td>
</tr>
<tr>
<td>Hydrocodone⁹</td>
<td>–</td>
<td>30–45 mg</td>
<td>–</td>
<td>3–5 h</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>1 mg</td>
<td>10 mg</td>
<td>10</td>
<td>3–6 h</td>
</tr>
<tr>
<td>Codeine⁴,¹⁰</td>
<td>–</td>
<td>200 mg</td>
<td>–</td>
<td>3–4 h</td>
</tr>
<tr>
<td>Tramadol¹¹</td>
<td>100 mg</td>
<td>300 mg</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td>Tapentadol¹²</td>
<td>–</td>
<td>75–100 mg</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

⁴Codeine, morphine, hydromorphone, hydrocodone, and oxymorphone should be used with caution in patients with fluctuating renal function due to potential accumulation of renally cleared metabolites—monitor for neurologic adverse effects.

⁵Conversion factor listed for chronic dosing.

⁶On single-dose administration, 10 mg IV morphine is equivalent to approximately 100 mcg IV fentanyl but with chronic fentanyl administration, the ratio of 10 mg IV morphine is equivalent to approximately 250 mcg IV fentanyl. For transdermal fentanyl conversions, (See PAIN-E 10 of 13).

⁷Long half-life, observe for drug accumulation and adverse effects, especially over first 4–5 days. In some individuals, steady state may not be reached for several days to 2 weeks. Methadone is typically dosed every 8–12 h.

⁸The oral conversion ratio of methadone varies. PRACTITIONERS ARE ADVISED TO CONSULT WITH A PAIN OR PALLIATIVE CARE SPECIALIST IF THEY ARE UNFAMILIAR WITH METHADONE PRESCRIBING. (See Special Notes Regarding Oral Methadone, PAIN-E 12 of 13).

⁹Equivalency data not substantiated. Clinical experience suggests use as a mild, initial-use opioid but effective dose may vary. Immediate-release hydrocodone is only available commercially combined with acetaminophen (325 mg/tablet) or ibuprofen (200 mg/tablet). The FDA has limited the amount of acetaminophen in all prescription drug products to no more than 325 mg per dosage unit. Dosage must be monitored for safe limits of ASA or acetaminophen.

¹⁰Codeine has no analgesic effect unless it is metabolized into morphine by hepatic enzyme CYP2D6 and then to its active metabolite morphine-6-glucuronide by phase II metabolic pathways. Individuals with low CYP2D6 activity may receive no analgesic effect from codeine, but rapid metabolizers may experience toxicity from higher morphine production. Dosage must be monitored for safe limits as it may be available in combination with acetylsalicylic acid (ASA) or acetaminophen. Dose listed refers only to opioid portion.

¹¹The manufacturer recommends a maximum single dose of tramadol not to exceed 100 mg, with a maximum daily dose of 400 mg for IR formulations (300 mg/d in older adults, 200 mg/d for renal impairment) or 300 mg/d for ER formulations.

¹²The maximum daily dose for tapentadol ER is 500 mg, or 600 mg IR (lower doses are recommended for moderate hepatic impairment, avoid with severe impairment).

¹³Shorter time generally refers to parenterally administered opioids (except for controlled-release products, which have some variability); longer time generally applies to oral dosing.

¹⁴Not recommended for cancer pain management because of CNS toxic metabolite - normeperidine.

¹⁵Mixed agonists-antagonists have limited usefulness in cancer pain; however, they can be used to treat opioid-induced pruritus. They should NOT be used in combination with opioid agonist drugs. Converting from an agonist to an agonist-antagonist could precipitate a withdrawal crisis in the opioid-dependent patient.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Continued on next page**

---

Adjuvant Medications for Neuropathic Pain

**ANTI DEPRESSANTS**
- TCAs
  - Amitryptyline
  - Imipramine
  - Nortriptyline
  - Desipramine
- SSRI and SSNRIs
  - Venlafaxine
  - Duloxetine

**ANTI CONVULSANTS**
- Gabapentin
- Pregabalin

For additional resources, see also NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Adult Cancer Pain
Adjuvant Treatments for Inflammatory Bone Pain

- NSAIDs
- Lidocaine patch
- Selective COX 2 inhibitors
- Steroids
- Bisphosphonates or denosumab
- Radiation therapy
- Nerve block (example, rib pain)
- Vertebral augmentation
- Radiofrequency ablation

For additional resources, see also [NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Adult Cancer Pain](#)
Opioid Poorly-Responsive Pain

- **Evaluate for:**
  - Cancer progression
  - Opioid tolerance (rapid dose escalation with no analgesic effect)
  - Dose-limiting opioid toxicity
  - Poor oral or skin absorption
  - Psychological component to pain
  - Misuse or abuse of opioid
Psychological Component to Pain

- **Total Pain Concept** – coined by Dame Cicely Saunders
  - Physical
  - Anxiety
  - Interpersonal
  - Not accepting

- **Not all pain is physical**
  - Utilize colleagues in psychiatry, social work and chaplaincy to address non-physical sources of distress
  - Consider prescribing benzodiazepines for anxiety

Summary of Points Covered

In this training module we addressed:

• Options for pain management including opioids and adjuvant medications
• Opioid pharmacology
• Optimal dosing of opioids
• Conversion from one opioid to another
Next Steps
For more detailed training on this topic you can go to the following resources:

**National Comprehensive Cancer Network® (NCCN®)**

- **NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Adult Cancer Pain Version 1.2018**

- **NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Palliative Care Version 1.2018. PAL-10, page 15 of 96**

**Education and Training for Health Professionals, EPEC-O**

- **The EPEC™-O Project, Module 2 – Cancer pain Management**

**Fast Facts**

- **Palliative Care Network of Wisconsin, Fast Fact and Concepts**
  [http://www.mypcnow.org/#!fast-facts/c6xb](http://www.mypcnow.org/#!fast-facts/c6xb)

- **Oral vs. Intravenous Acetaminophen #302**
  - [Tramadol in Palliative Care #290](http://www.mypcnow.org/#!fast-facts/c6xb)
  - [A Comparison of Pregabalin and Gabapentin in Palliative Care #289](http://www.mypcnow.org/#!fast-facts/c6xb)
  - [Opioid Poorly-Responsive Cancer Pain #215](http://www.mypcnow.org/#!fast-facts/c6xb)
  - [Calculating Opioid Dose Conversions #36](http://www.mypcnow.org/#!fast-facts/c6xb)
  - [Converting To Transdermal Fentanyl #2](http://www.mypcnow.org/#!fast-facts/c6xb)
  - [Oral vs. Intravenous Acetaminophen #302](http://www.mypcnow.org/#!fast-facts/c6xb)
  - [Tramadol in Palliative Care #290](http://www.mypcnow.org/#!fast-facts/c6xb)
Faculty Bio for Shelly Lo, MD

Shelly Lo, MD is an associate professor of medicine at Loyola University Medical Center. As a medical oncologist, she specializes in treatment of breast and GI malignancies and is director of Loyola’s Cancer Risk Assessment and Prevention Clinic.

She is an associate medical director for Loyola Hospice. She is board certified in Medical Oncology and Hospice and Palliative Care.

For more Information:

https://www.loyolamedicine.org/doctor/shelly-lo
Joanna Martin MD is board certified in Internal Medicine, Geriatrics, and Hospice, and Palliative Medicine. She is a palliative care physician at the Jesse Brown VA and a Health Systems Clinician at Northwestern Memorial Hospital. Dr. Martin was previously employed by Horizon Hospice and Palliative Care and Presence St. Joseph Hospital in Lincoln Park from 2006 through 2015. She was medical director of Horizon Hospice and Palliative Care and the Director of Palliative Care at Presence St. Joseph Hospital from 2007 through 2015.

As a clinician educator, Dr. Martin has experience educating all levels of learners in geriatrics and palliative care in the home and hospital setting. She is currently serving as a Design Team Leader for the Coleman Supportive Oncology Initiative, a multi-hospital initiative to improve access to supportive oncology services. Dr. Martin attended medical school at the University of Minnesota Medical School in Minneapolis and completed an Internal Medicine residency and two year Geriatrics Fellowship at the University of Chicago.
References


U.S. Food and Drug Administration, Full prescribing information for morphine sulfate injection USP. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202515s000lbl.pdf

Whitten, Donovan, Cristobal. Treating chronic pain: new knowledge, more choices. The Permanente Journal 2005; 9(4): 9-18: Figure 7 and Figure 8. www.thelpermanentejournal.org

